HomeFUNDINGPMC Capital Acquires the Assets of Ransom & Randolph Company from Dentsply Sirona

PMC Capital Acquires the Assets of Ransom & Randolph Company from Dentsply Sirona

February 2, 2021

PMC Capital notes that Ransom & Randolph Company, is a leading mission-critical manufacturer and supplier of specialty consumables to the global investment casting industry, serving aerospace, defense, industrial gas turbine, automotive, commercial, jewelry, dental, and art casting markets from Dentsply Sirona, Inc.

Financial terms of the transaction were not disclosed.

The divestment of Ransom & Randolph is part of Dentsply Sirona’s strategy to focus on its core business.

“We are extremely thrilled that this transaction creates an opportunity from which both sides will benefit. As Ransom & Randolph looks forward to the future, the roadmap will be to execute a growth model which includes strategic acquisition and organic growth,” says Michel Tamer, Managing Partner of PMC Capital.

“As an independent business, Ransom & Randolph will strengthen its focus on our industrial foundry, jewelry and dental lab customer base, while also remaining an important partner to Dentsply Sirona. The R&R team and I are eager to serve our customers in new and exciting ways,” says Daniel Nixon, President of Ransom & Randolph.

Founded in 1872, Ransom & Randolph is dedicated to advancing the global investment casting industry. Ransom & Randolph has provided foundries, dental labs, and jewelers with extensive process knowledge, exceptional technical expertise and innovative product technology since the 1800s. By coupling revolutionary product developments with experienced staff, manufacturing and warehousing facilities worldwide, Ransom & Randolph successfully helps customers become casting industry leaders.

CriticalPoint Partners, LLC served as Dentsply Sirona’s exclusive financial advisor for the transaction. 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy